Comparison
13q Partial Monosomy Syndrome C0265451 vs 2 Hydroxyphenylacetic Aciduria C5937087
Clinical comparison between 13q Partial Monosomy Syndrome and 2 Hydroxyphenylacetic Aciduria for differential diagnosis and treatment planning.
13q Partial Monosomy Syndrome C0265451
A rare genetic condition involving deletion of material from chromosome 13. It can lead to developmental delays, growth concerns, and various physical features. Treatment involves supportive care addressing each individual's specific challenges.
2 Hydroxyphenylacetic Aciduria C5937087
A rare metabolic disorder where the body cannot properly process certain acids. It may cause neurological issues and is typically identified in infancy. Management involves diet modifications and supportive care.
6 comparison axes
Onset
13q Partial Monosomy Syndrome C0265451
0-null
2 Hydroxyphenylacetic Aciduria C5937087
0-null
Onset patterns differ
Severity
13q Partial Monosomy Syndrome C0265451
severe
2 Hydroxyphenylacetic Aciduria C5937087
moderate
Different severity levels
Chronic
13q Partial Monosomy Syndrome C0265451
Chronic
2 Hydroxyphenylacetic Aciduria C5937087
Chronic
Differing course
Communicable
13q Partial Monosomy Syndrome C0265451
No
2 Hydroxyphenylacetic Aciduria C5937087
No
Different transmission
Body System
13q Partial Monosomy Syndrome C0265451
congenital
2 Hydroxyphenylacetic Aciduria C5937087
metabolic
Same/different system
Category
13q Partial Monosomy Syndrome C0265451
genetic
2 Hydroxyphenylacetic Aciduria C5937087
metabolic
Different category
Bottom line
13q-partial-monosomy-syndrome-C0265451 and 2-hydroxyphenylacetic-aciduria-C5937087 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 13q Partial Monosomy Syndrome C0265451 | 2 Hydroxyphenylacetic Aciduria C5937087 | Discriminating power |
|---|---|---|---|
| Developmental pattern | May involve early developmental delay and growth concerns from a congenital chromosomal change. | May involve neurologic concerns, often recognized in infancy; a uniform pattern is not established. | Moderate |
| Physical features | Variable congenital physical features may occur, but none are definitive alone. | No specific congenital malformation pattern is established in the supplied description. | Moderate |
| Metabolic abnormality | Not primarily defined by abnormal organic-acid excretion. | Named for 2-hydroxyphenylacetic acid in urine, an abnormal result requiring interpretation. | High |
When to favor each condition
Choose 13q Partial Monosomy Syndrome C0265451 when
Congenital or growth concerns suggest a chromosomal cause
The left concept is a genetic deletion rather than a urine metabolite finding.
Moderate
Genetic confirmation of missing 13q material is sought
Chromosome-based testing directly addresses this condition.
High
Multiple developmental and physical findings occur together
This pattern fits the supplied congenital genetic description better than an isolated aciduria.
Moderate
Choose 2 Hydroxyphenylacetic Aciduria C5937087 when
Urine testing shows 2-hydroxyphenylacetic acid
The right concept begins as a laboratory abnormality, not proof of a specific disease.
High
An infant has neurologic or metabolic concerns
The source links possible neurologic issues and usual identification in infancy.
Moderate
Clinicians must separate metabolite from diagnosis
The result may need correlation with cause, diet, and other metabolic findings.
High
How key tests differ
| Test | 13q Partial Monosomy Syndrome C0265451 | 2 Hydroxyphenylacetic Aciduria C5937087 | Interpretation |
|---|---|---|---|
| Karyotype or chromosomal microarray | May show partial loss of chromosome 13 material. | Not expected to establish this aciduria. | A positive genetic result supports the left concept; a normal result does not exclude the right. |
| Urine organic acid analysis | No characteristic organic-acid pattern is established here. | May show 2-hydroxyphenylacetic acid; no cutoff is supplied. | An abnormal result requires clinical correlation and is not automatically a diagnosis. |
| Developmental and metabolic assessment | Emphasizes growth, development, and congenital findings. | Emphasizes neurologic status, feeding, and metabolic context. | Assessment guides care but does not establish prognosis from these data. |
Prognosis comparison
13q Partial Monosomy Syndrome C0265451
- Outcome
- Often chronic and potentially severe, but individual outcome is variable and not quantified.
- Factors
- Deletion extent, affected systems, and developmental support may influence course.
2 Hydroxyphenylacetic Aciduria C5937087
- Outcome
- Described as moderate and chronic, although prognosis is not established by these data.
- Factors
- Underlying cause, neurologic involvement, and response to supportive care may matter.
Time frame: Long-term follow-up may be needed; the exact course is uncertain.
Associated findings, early evaluation, and access to specialist care influence planning.
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental or neurologic difficulty | Developmental delay may occur with variable severity. Neurologic issues are possible but not uniformly established. Individual evaluation is needed; no definitive symptom list is supplied. |
| Growth or nutrition concern | Growth concerns may accompany the chromosomal condition. Diet modification may be considered, but no specific regimen is established. Nutrition advice should come from a clinician; doses are not provided. |
| Diagnostic uncertainty | Effects may vary with deletion extent, which is not specified here. Aciduria may be primary or secondary; the name alone does not prove the cause. Specialist interpretation is recommended for both concepts. |
Patient education highlights
- HighFinding versus diagnosis
The left is a chromosomal condition; the right starts as an abnormal urine result that may or may not indicate a disorder.
- HighIndividualized care
Both generally need supportive care tailored to the person. Exact treatments and doses are not established here.
- MediumWhen to seek review
Report changes in development, growth, feeding, alertness, or neurologic function for clinician assessment.